MDACC Study No:2012-0750 ( NCT No: NCT01786135)
Title:A phase 1, open-label, dose-escalation study of SGN-CD19A in
patients with relapsed or refractory B-lineage non-Hodgkin
Principal Investigator:Michelle A. Fanale
Treatment Agent:SGN-CD19A
Study Status:Closed
Study Description:The goal of this retreatment portion of the study is to study the safety of
this drug and the effect, if any, SGN-CD19A may have on the disease.

SGN-CD19A is designed to attach to a protein called CD19 on the surface of
cancer cells and then release a poison that may cause the cells to die.

This is the first study using SGN-CD19A in humans.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:SGN-CD19A
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults